1. Home
  2. COUR vs SLNO Comparison

COUR vs SLNO Comparison

Compare COUR & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COUR
  • SLNO
  • Stock Information
  • Founded
  • COUR 2012
  • SLNO 1999
  • Country
  • COUR United States
  • SLNO United States
  • Employees
  • COUR N/A
  • SLNO N/A
  • Industry
  • COUR Computer Software: Prepackaged Software
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • COUR Technology
  • SLNO Health Care
  • Exchange
  • COUR Nasdaq
  • SLNO Nasdaq
  • Market Cap
  • COUR 1.2B
  • SLNO 1.9B
  • IPO Year
  • COUR 2021
  • SLNO 2014
  • Fundamental
  • Price
  • COUR $7.31
  • SLNO $48.54
  • Analyst Decision
  • COUR Buy
  • SLNO Strong Buy
  • Analyst Count
  • COUR 10
  • SLNO 7
  • Target Price
  • COUR $15.10
  • SLNO $67.14
  • AVG Volume (30 Days)
  • COUR 1.5M
  • SLNO 561.3K
  • Earning Date
  • COUR 10-24-2024
  • SLNO 08-07-2024
  • Dividend Yield
  • COUR N/A
  • SLNO N/A
  • EPS Growth
  • COUR N/A
  • SLNO N/A
  • EPS
  • COUR N/A
  • SLNO N/A
  • Revenue
  • COUR $673,825,000.00
  • SLNO N/A
  • Revenue This Year
  • COUR $12.29
  • SLNO N/A
  • Revenue Next Year
  • COUR $12.42
  • SLNO N/A
  • P/E Ratio
  • COUR N/A
  • SLNO N/A
  • Revenue Growth
  • COUR 16.19
  • SLNO N/A
  • 52 Week Low
  • COUR $6.35
  • SLNO $3.73
  • 52 Week High
  • COUR $21.26
  • SLNO $53.82
  • Technical
  • Relative Strength Index (RSI)
  • COUR 37.84
  • SLNO 53.45
  • Support Level
  • COUR $7.84
  • SLNO $45.90
  • Resistance Level
  • COUR $8.18
  • SLNO $49.61
  • Average True Range (ATR)
  • COUR 0.31
  • SLNO 2.71
  • MACD
  • COUR -0.10
  • SLNO -2.71
  • Stochastic Oscillator
  • COUR 2.73
  • SLNO 92.67

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Share on Social Networks: